



LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

02486.0065.NPUS01

APPLICATION NO.

10/698,078

APPLICANT

Cynthia B. Robinson, et al.

FILING DATE

October 29, 2003

GROUP

1624

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ll	1.	3,994,974	Nov. 1976	Murakami et al			
	2.	4,393,066	Jul. 1983	Garrett et al.			
	3.	4,499,064	Feb. 1985	Shive			
	4.	4,575,498	Mar. 1986	Holmes et al.			
	5.	4,600,710	Jul. 1986	Liang et al.			
	6.	4,628,052	Dec. 1986	Peat			
	7.	4,894,219	Jan. 1990	Baker et al.			
	8.	4,920,115	Apr. 1990	Nestler et al.			
	9.	4,931,441	Jun. 1990	Lawrence			
	10.	4,985,443	Jan. 1991	Montes			
	11.	4,992,474	Feb. 1991	Skidmore et al.			
	12.	5,021,417	Jun. 1991	Prost			
	13.	5,059,595	Oct. 1991	Le Grazie			
	14.	5,077,284	Dec. 1991	Loria et al.			
	15.	5,108,363	Apr. 1992	Tuttle et al.			
	16.	5,110,810	May 1992	Eich et al.			
	17.	5,118,505	Jun. 1992	Költringer			
	18.	5,126,375	Jun. 1992	Skidmore et al.			
	19.	5,162,198	Nov. 1992	Eich et al.			
	20.	5,173,488	Dec. 1992	Haeger			
	21.	5,177,076	Jan. 1993	Nijkerk et al.			
	22.	5,225,445	Jul. 1993	Skidmore et al.			
	23.	5,234,404	Aug. 1993	Tuttle et al.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0065.NPUS01	10/698,078
	APPLICANT	
	Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1624

24.	5,258,385	Nov. 1993	Dodd et al.				
25.	5,266,312	Nov. 1993	Leung et al.				
26.	5,270,305	Dec. 1993	Palmer				
27.	5,286,252	Feb. 1994	Tuttle et al.				
28.	5,347,005	Sep. 1994	Mueller et al.				
29.	5,407,684	Apr. 1995	Loria et al.				
30.	5,407,927	Apr. 1995	Morales et al.				
31.	5,460,605	Oct. 1995	Tuttle et al.				
32.	5,489,581	Feb. 1996	Daynes et al.				
33.	5,527,789	Jun. 1996	Nyce				
34.	5,532,230	Jul. 1996	Daynes et al.				
35.	5,538,734	Jul. 1996	Le Grazie				
36.	5,583,126	Dec. 1996	Daynes et al.				
37.	5,635,496	Jun. 1997	Daynes et al.				
38.	5,660,835	Aug. 1997	Nyce				
39.	5,684,199	Nov. 1997	Francotte				
40.	5,686,438	Nov. 1997	Daynes et al.				
41.	5,703,063	Dec. 1997	Chasalow, et al.				
42.	5,767,278	Jun. 1998	Gaeta et al.				
43.	5,811,418	Sep. 1998	Daynes et al.				
44.	5,859,000	Jan. 1999	Dowell et al.				
45.	5,861,391	Jan. 1999	Yen et al.				
46.	5,948,434	Sep. 1999	Labrie				
47.	6,087,351	Jul. 2000	Nyce				
48.	6,093,706	Jul. 2000	Zeligs				
49.	6,156,503	Dec. 2000	Drazen et al.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0065.NPUS01	10/698,078
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1624

50.	6,297,382	Oct. 2001	Scott				
51.	6,441,181	Aug. 2002	Scott				
52.	6,488,027	Dec. 2002	Moulin				
53.	2002/0042401	Apr. 2002	Ferguson et al.				
54.	2003/0013772	Jan. 2003	Murphy et al.				
55.	2003/0138434	Jul. 2003	Campbell et al.				
56.	2003/0139331	Jul. 2003	Martin et al.				
57.	2003/0216329 A1	Nov. 2003	Robinson et al.				
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
58. X	WO 93/16704		PCT				
59. X	WO 96/16680		PCT				
60. X	WO 97/48367		PCT				
61. X	WO 98/03180		PCT				
62. X	WO 00/54763		PCT				
63. X	WO 01/015745		PCT				
64. X	WO 02/069955		PCT				
65. X	WO 02/85296		PCT				
66. X	WO 03/072572		PCT				
67. X	WO 04/014293 A2		PCT				

NOT Considered

not considered DOC

 6/19/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO. 02486.0065.NPUS01	APPLICATION NO. 10/698,078
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1624

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
68.	X	Araneo et al., "Dehydroepiandrosterone Reduces Progressive Dermal Ischemia Caused by Thermal Injury", <i>J. Surg. Res.</i> 59(2):250-62 (1995).
69.	X	Bonnett et al., "Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension," <i>PNAS</i> 100(16):9488-93 (2003).
70.	X	Budavari, The Merck Index 11 th ed., 1989, pp. 660-661, monograph 4141.
71.	X	Coleridge et al., "Intravenous aminophylline confers no benefit in acute asthma treated with intravenous steroids and inhaled bronchodilators", <i>Aust. N.Z. J. Med.</i> 23:348-54 (1993).
72.	X	Dashtaki et al., "Dehydroepiandrosterone and Analogs Inhibit DNA Binding of AP-1 and Airway Smooth Muscle Proliferation", <i>J. Pharmacol. Exp. Ther.</i> 285(2):876-83 (1998).
73.	X	Dompeling et al., "Treatment with Inhaled Steroids in Asthma and Chronic Bronchitis: Long Term Compliance and Inhaler Technique", <i>Family Practice</i> 9(2):161-6 (1992).
74.	X	Dunn, et al., "Dehydroepiandrosterone sulphate concentrations in asthmatic patients: pilot study," <i>N.Z. J. Med.</i> 97(768):805-8 (1984).
75.	X	Duplantier, et al., Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes", <i>DDT</i> 1(5):199-207 (1996)
76.	X	Dworski et al., "Conspectus: Inhaled Steroids in Asthma", <i>Comprehensive Therapy</i> , 18:3 (1992).
77.	X	Fehér et al., "Adrenocortical Function in Bronchial Asthma", <i>Acta Medica Hungarica</i> 40(2-3):125-32 (1983).
78.	+	Fehér, et al., "Dehydroepiandrosterone Therapy of Patients with Corticosteroid Dependent Bronchial Asthma," <i>Natl. Institute of Rheumatism and Physiotherapy, in XIII Congress of the European Academy of Allergology and Clinical Immunology</i> , eds. (Saba, et al., Debrecen Hungary (1986).
79.	X	Hampel et al., "Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats," <i>J. Eur. Respir.</i> 21:862-5 (2003).
80.	↑	Holzmann et al., "Therapy of Psoriasis with Dehydroepiandrosterone-Enanthate. II. Intramuscular Depot Application of 300 mg", <i>Arch. Dermatol. Forsch.</i> 247(1):23-8 (1973) (German with English Abstract).
81.	✓	Hummel et al., "Comparison of oral-steroid sparing by high-dose and low-dose inhaled steroid in maintenance treatment of severe asthma", <i>The Lancet</i> , 340(8834/8835):1483-7 (1992).
82.	✓	Itagaki et al., "Effect of Cortisol on the Release of Human Decidual", <i>Caplus</i> , 114875 (1991). (Japanese with English Abstract).

NO received DOC

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	02486.0065.NPUS01	10/698,078
	APPLICANT	
	Cynthia B. Robinson, et al.	
	FILING DATE	GROUP
	October 29, 2003	1624

83.	X	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchical Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (Hungarian).
84.	X	Koó et al., "Our experiences with Dehydroepiandrosterone Therapy in Steroid-Dependent Intrinsic Bronchical Asthma", <i>Orvosi Hetilap</i> 128(38):1995-7 (1987) (English translation).
85.	+	Lejeune, "Pathogenesis of Mental Impairment in Trisomy 21", <i>Annales de Génétique</i> , 92:27643 (1996) (French with English Abstract).
86.	+	Mileva et al., "Androstenedione, DHEA sulfate, cortisol, aldosterone and testosterone in bronchial asthma patients", 07608054 (1990) (Russian with English Abstract).
87.	+	Nakagawa, et al., "The Properties of Water of Crystallization of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 29(5):1466-9 (1981)
88.	+	Nakagawa, et al., "The Grinding and Drying on the Solid State Stability of Sodium Prasterone Sulfate," <i>Chem. Pharm. Bull</i> 30(1):242-8 (1982)
89.	X	Pashko et al., "Inhibition of 7,12-dimethylbenz(a)anthracene-induced Skin Papillomas and Carcinomas by Dehydroepiandrosterone and 3-beta-methylandrost-5-en-17-one in mice", <i>Cancer Res.</i> 45(1):164-6 (1985).
90.	X	Peeters et al., "Differences in Purine Metabolism in Patients with Down's Syndrome", <i>J. Intellect. Diabil. Res.</i> 37:471 (1993). Abstract.
91.	X	Reed, "Aerosol Steroids as Primary Treatment of Mild Asthma", <i>New England J. Med.</i> , 325(6):425-6 (1991).
92.	X	Rowe et al., "Effectiveness of Steroid Therapy in Acute Exacerbations of Asthma: A Meta-analysis", <i>Amer. J. Emergency Med.</i> , 10(4):301-10 (1992).
93.	X	Sasaki et al., "Cervical Ripening with Dehydroepiandrosterone Sulphate", <i>Br. J. Obstet. Gynaecol.</i> 89(3):195-8, (1982).
94.	X	Sciarra et al., "Aerosols", Remington's Pharmaceutical Sciences, 18 th ed. (1990), Eds. Gennaro et al., pp. 1873-5 and 1694-1712.
95.	X	Sharma et al., "Screening of potential chemopreventive agents using biochemical markers of carcinogenesis", <i>Cancer Res.</i> 54(22):5848-55 (1994).
96.	X	Shomali, "The Use of Anti-Aging Hormones. Melatonin. Growth Hormone, Testosterone, and Dehydroepiandrosterone: Consumer Enthusiasm for Unproven Therapies", <i>Md. Med. J.</i> 46(4):181-6 (1997).
97.	X	Sonka et al., "Gout and Dehydroepiandrosterone: 3. DHEA Administration", <i>Endokrynologia Polska</i> 24(3):209-18 (1973).

no received doc

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> PTO FORM 1449	ATTY. DOCKET NO. 02486.0065.NPUS01	APPLICATION NO. 10/698,078
	APPLICANT Cynthia B. Robinson, et al.	
	FILING DATE October 29, 2003	GROUP 1624

	98.	Sur et al., "Double-blind trial pyroxidine (vitamin B6) in the treatment of steroid-dependent asthma", <i>Ann. Allergy</i> , 70:147-52 (1993).
	X 99.	Schwartz et al., "Inhibition of 7,12-dimethylbenz[a]anthracene- and urethan-induced lung tumor formation in A/J mice by long-term treatment with dehydroepiandrosterone," <i>Carcinogenesis</i> 2(12):1335-7 (1981)
	X 100.	Van de Graaf et al., "Respiratory Membrane Permeability and Bronchial Hyperreactivity in Patients with Stable Asthma: Effects of Therapy with Inhaled Steroids", <i>Bronchial Asthma and Respiratory Membrane Permeability</i> 143:362-8 (1991).
	101 X	Van Vollenhoven et al., "Dehydroepiandrosterone in SLE. Results of a Double-Blind, Placebo-Controlled, Randomized Clinical Trial.", <i>Arthritis Rheum.</i> 38(12): 1826-31 (1995).
	102. X	Wolkowitz et al., "Dehydroepiandrosterone Treatment of Depression", <i>Biol. Psychiatry</i> 41(3):311-8. (1997).

No Received Doc

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/698,078	
				Filing Date	October 29, 2003	
				First Named Inventor	Cynthia B. Robinson	
				Art Unit	1617	
				Examiner Name	Kevin J. Capps	
Sheet	1	Of	3	Attorney Docket Number		30775-713.201

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
UL	1.	US 2002/0032160	03/14/2002	Nyce		
UL	2.	US 6,635,629	10/21/2003	Raymond et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
UL	3.	Belgian Pat. No. 765,986	10/20/1971	Kaiser et al.		
UL	4.	Dutch Pat. No. 85197	1958	Netherlands		
UL	5.	Japanese Patent Application Public Open. No. 2676/1971	1971	Japan		

NOT considered
(not provided
by applicant)

Examiner Signature	<i>Chet Clerk</i>	Date Considered	6/29/2007
--------------------	-------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,078
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	2	Of	3	Attorney Docket Number	30775-713.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁴
W	6.	CRETICOS, P. S. Managing asthma in adults. Am J Manag Care. 2000; 6(17 Suppl):S940-63.	
W	7.	SASANO, et al. Brenner tumor of the ovary: immunoanalysis of steroidogenic enzymes in 23 cases. Hum Pathol. 1989; 20(11):1103-7.	
	8.	BAUER, et al. Prognostic implications of ploidy and proliferative activity in diffuse large cell lymphomas. Cancer Res. 1986; 46(6):3173-8.	
	9.	CLARK, et al. The effects of various methods of sacrifice and of ethanol on adenosine levels in selected areas of rat brain. J. Neurosci Methods. 1988; 25(3):243-9.	
	10.	HARTIALA, et al. Testosterone metabolism in dog lung in vitro. Steroids Lipids Res. 1973; 4(1):17-23.	
	11.	MILEWICH, et al. Androstenedione metabolism in human lung fibroblasts. J Steroid Biochem. 1986; 24(4):893-7.	
	12.	MILEWICH, et al. Metabolism of androsterone and 5 alpha-androstane-3 alpha,17 beta-diol in human lung tissue and in pulmonary endothelial cells in culture. J Clin Endocrinol Metab. 1985; 60(2):244-50.	
	13.	MILEWICH, et al. Metabolism of dehydroisoandrosterone and androstenedione in human pulmonary endothelial cells in culture. J Clin Endocrinol Metab. 1983; 56(5):930-5.	
	14.	MILEWICH, et al. Metabolism of dehydroisoandrosterone and androstenedione by the human lung in vitro. J Steroid Biochem. 1977; 8(4):277-84.	
	15.	MILEWICH, et al. Testosterone metabolism by human lung tissue. J Steroid Biochem. 1978; 9(1):29-32.	

Examiner Signature	<i>Kevin J. Capps</i>	Date Considered	6/29/03
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

3060427_1.DOC

Attorney Docket No. 30775-713.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/698,078
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	3	Of	3	Attorney Docket Number	30775-713.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	16.	PONGRACZ, et al. Capillary gas chromatography of urinary steroids of terbutaline-treated asthmatic children. Chromatographia. 1998; 48(1/2): 163-165.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.


3060427_1.DOC
Attorney Docket No. 30775-713.201

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,078
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	1	Of	2	Attorney Docket Number	30775-713.201

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
W	1.	US 2004/0067920	04/08/2004	Leonard et al.	
	2.	US 2004/0082522	04/29/2004	Nyce	
	3.	US 2005/0113318	05/26/2005	Robinson et al.	
	4.	US 4,501,729	02/26/1985	Boucher et al.	
	5.	US 4,956,355	09/11/1990	Prendergast	
	6.	US 5,859,000	01/12/1999	Dowell et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	7.	EP 429187 B1	01/05/1994	Bourke et al.		
	8.	GB 2240472 A	08/07/1991	Masterson		
	9.	WO 91/04030 A1	04/04/1991	Daynes et al.		
	10.	WO 96/25935 A1	08/29/1996	Nyce		
✓	11.	WO 2005/005805 A2	01/20/2005	Sharpe		

Examiner Signature		Date Considered	6/19/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/698,078
				Filing Date	October 29, 2003
				First Named Inventor	Cynthia B. Robinson
				Art Unit	1617
				Examiner Name	Kevin J. Capps
Sheet	2	Of	2	Attorney Docket Number	30775-713.201

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	12.	ABOU-GHARBIA, et al. Synthesis of dehydroepiandrosterone sulfatide and 16 alpha-halogenated steroids. J Pharm Sci. 1981; 70(10):1154-7.	
	13.	FOLKERS, et al. Lovastatin-decreases coenzyme Q levels in humans. Proc Natl Acad Sci U S A. 1990;87(22):8931-4.	
	14.	GREENBERG, et al. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol. 1990; 30(7):596-608.	
	15.	ISHIHARA, et al. Gas chromatographic determination of degradation products and stability of dehydroepiandrosterone. Drug Develop. Ind. Pharm. 1979; 5(3):263-275.	
	16.	MORTENSEN, et al. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure. Int J Tissue React. 1990;12(3):155-62.	
	17.	TYCZYNSKI, et al. Lung cancer in Europe in 2000: epidemiology, prevention, and early detection. Lancet Oncol. 2003; 4(1):45-55.	

UNPUBLISHED PATENT APPLICATIONS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
VR	18.	LEONARD, et al. US Patent Application No. 10/462,927, entitled "Dihydrate dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof," filed June 17, 2003. (WSGR Reference No. 30775-722.201)	

Examiner Signature	<i>[Signature]</i>	Date Considered	6/29/2007
--------------------	--------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.